Literature DB >> 4714098

An analysis of six patients with Parkinson's disease who have been unresponsive to L-dopa therapy.

R J Mones.   

Abstract

Six patients diagnosed as Parkinson's disease on a clinical basis alone are described, and their response to L-dopa and to alpha methyl dopa hydrazine (MK 486) and L-dopa. They are compared with 239 other patients with Parkinson's disease treated in the same time period. These six patients were unusual in that they did not have a clinical response to L-dopa, nor did they develop dyskinesias on L-dopa or on L-dopa with MK 486, although they showed high blood levels of L-dopa and high homovanillic acid levels in the spinal fluid. Unresponsiveness to L-dopa is attributed to a specific brain mechanism and not to problems of transport of L-dopa to the brain or to abnormal peripheral metabolism of L-dopa. The term `motor unresponsiveness to L-dopa' may be useful to describe such patients who may eventually be shown to be suffering from diseases other than Parkinsonism.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4714098      PMCID: PMC494334          DOI: 10.1136/jnnp.36.3.362

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  15 in total

1.  Modification of Parkinsonism--chronic treatment with L-dopa.

Authors:  G C Cotzias; P S Papavasiliou; R Gellene
Journal:  N Engl J Med       Date:  1969-02-13       Impact factor: 91.245

2.  Striatonigral degeneration. Clinical-pathological correlations and response to stereotaxic surgery.

Authors:  J M Andrews; R D Terry; J Spataro
Journal:  Arch Neurol       Date:  1970-10

Review 3.  Cerebral metabolites in cerebrospinal fluid as a biochemical approach to the brain.

Authors:  A T Moir; G W Ashcroft; T B Crawford; D Eccleston; H C Guldberg
Journal:  Brain       Date:  1970       Impact factor: 13.501

4.  Aromatic amino acids and modification of parkinsonism.

Authors:  G C Cotzias; M H Van Woert; L M Schiffer
Journal:  N Engl J Med       Date:  1967-02-16       Impact factor: 91.245

5.  Treatment of parkinsonism with levodopa.

Authors:  M D Yahr; R C Duvoisin; M J Schear; R E Barrett; M M Hoehn
Journal:  Arch Neurol       Date:  1969-10

6.  Evaluation of L-dopa therapy in Parkinson's disease.

Authors:  R J Mones; T S Elizan; G J Siegel
Journal:  N Y State J Med       Date:  1970-09-15

7.  Brain capillaries as a source of homovanillic acid in cerebrospinal fluid.

Authors:  G Bartholini; R Tissot; A Pletscher
Journal:  Brain Res       Date:  1971-03-19       Impact factor: 3.252

8.  The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid pressure. Observations on cerebrospinal fluid hydrodynamics.

Authors:  S Hakim; R D Adams
Journal:  J Neurol Sci       Date:  1965 Jul-Aug       Impact factor: 3.181

9.  L-dopa in Parkinsonism associated with cerebellar dysfunction (probable olivopontocerebellar degeneration).

Authors:  H L Klawans; E Zeitlin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1971-02       Impact factor: 10.154

10.  Treatment of Parkinson's syndrome with L dihydroxyphenylalanine (levodopa).

Authors:  F McDowell; J E Lee; T Swift; R D Sweet; J S Ogsbury; J T Kessler
Journal:  Ann Intern Med       Date:  1970-01       Impact factor: 25.391

View more
  6 in total

Review 1.  Parkinson's disease and levodopa. A five-year follow-up and review.

Authors:  C H Markham; L J Treciokas; S G Diamond
Journal:  West J Med       Date:  1974-09

2.  An extended clinical trial to compare levodopa and amantadine used as single drugs with both drugs used incombination in Parkinson's Disease.

Authors:  N Calaghan; M McIlroy; M O'Connor
Journal:  Ir J Med Sci       Date:  1974-03       Impact factor: 1.568

3.  Editorial: Failure to respond to levodopa.

Authors: 
Journal:  Br Med J       Date:  1973-11-10

Review 4.  Clinical pharmacokinetics of levodopa in parkinson's disease.

Authors:  J R Bianchine; G M Shaw
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

Review 5.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

Review 6.  Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors:  Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Front Cell Neurosci       Date:  2014-11-11       Impact factor: 5.505

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.